Antibody to human T lymphotropic virus type 1I1 (anti-HTLV-III) 
Introduction
The acquired immunodeficiency syndrome (AIDS) is a recently recognised infectious disease that is now prevalent in several American and European cities. By the end of November 1984 some 6993 American and at least 580 European cases, including 102 British ones, had been reported (Centers for Disease Control, Atlanta, AIDS Activity Weekly Report; WHO Collaborating Centre on AIDS, Paris; PHLS Communicable Disease Surveillance Centre, London; all unpublished). AIDS is usually transmitted by sexual intercourse but can also spread through blood and blood products. Cases have occurred mostly in homosexual men, but also in haemophiliacs, intravenous drug abusers, and recipients of blood transfusions.
AIDS is probably caused by a single, rather heterogeneous virus. This was first described as lymphadenopathy associated virus' and then as human T lymphotropic virus type III (HTLV-III).2 The virus probably acts by progressively depleting the T4 "helper" lymphocyte population through persistent infection.3 While some patients infected with HTLV-III develop AIDS-that is, frank immunodeficiency with opportunistic infections and malignancies-more have features such as fever, fatigue, weight loss, diarrhoea, and lymphadenopathy ( For the immunofluorescence test HT/H9/3 and HT/H9 cells were gently centrifuged and the deposit resuspended in phosphate buffered saline. Ten sl volumes were applied to coverslips, dried in air, fixed in acetone for 10 minutes and exposed to ultraviolet light for 20 minutes. The coverslips were stored at -20f C until used. Sera were inactivated at 56°C for 30 minutes and applied, at a dilution of 1/8, to the cell preparations. After one hour at 37'C in a moist chamber and three 10 minute washes in phosphate buffered saline the coverslips were dried and 10 ,sl of fluorescein conjugated antihuman IgG applied to each preparation. After further incubation for one hour and three 10 minute washes, the coverslips were dried, fixed to microscope slides with polyvinyl alcohol, and examined microscopically in ultraviolet light. Anti-HTLV-III positive and negative control sera were included in each batch of tests. Sera that gave rise to fluorescence in HT/H9,3 but not in HT/H9 cells were scored as strongly or weakly positive according to brightness.
Fluorescence did not occur in HT, H9 cells.
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Drug abusers-Sera from 203 intravenous drug abusers from all over England were examined. Most had a clinical diagnosis of acute viral hepatitis and 152 had hepatitis B surface antigen (HBsAg) in their serum. Five (2 5o0), including three who were positive for HBsAg, were also positive for HTLV-III.
Results
Assessment of radjoimmunoassay and immunofluorescence tests for anti-HTL V-III-Fifty out of 50 blood donations, 50 out of 50 immunosuppressed patients, and 23 out of 23 recipients of hepatitis B virus vaccine sampled three to six months after the third dose of vaccine were anti-HTLV-III negative by radioimmunoassay. Twelve out of 12 patients with AIDS were anti-HTLV-III positive by radioimmunoassay and by the immunofluorescence test. The first 192 sera examined that were negative by radioimmunoassay were all negative by immunofluorescence testing and, thereafter, only sera positive by radioimmunoassay were tested by immunofluorescence. Four out of 273 of these sera positive by radioimmunoassay were negative by immunofluorescence testing (table I) .
Homosexual patients-In London sera from homosexuals attending clinics for sexually transmitted diseases were tested. The proportion who were anti-HTLV-III positive rose steadily from 1980 to 1984, and in 1984 a third of those sampled were positive (table II) . Outside London sera collected, mostly during 1984, from homosexual patients at clinics in five provincial centres were tested. The prevalence of anti-HTLV-III ranged from 1-6t to 112°o and was 51°O overall (table III) . 
Discussion
Though it cannot be assumed that all individuals infected with HTLV-III have antibody to it, the need for convenient, sensitive, and specific tests for anti-HTLV-III is indisputable. The competitive radioimmunoassay, a one step multiwell method, as well as being suitable for large seroepidemiological surveys, has been extensively used in assays for antibodies to hepatitis and herpes viruses7-9 and has proved both specific and sensitive. Our results and those of others6 on blood donors and other groups indicate that it is a specific method for anti-HTLV-III, and this may be an advantage over the enzyme assays now under development, in which it has been suggested that many false positive reactions may occur.i0 The competitive radioimmunoassay for anti-HTLV-III is also adequately sensitive. A whole virus antigen capable of detecting a broad spectrum of antibodies is used, and almost all patients with AIDS have anti-HTLV-III detectable by it.6 The immunofluorescence test used in this study was based on acetone fixed cells and approached the radioimmunoassay in sensitivity. In both procedures steps were taken (p propiolactone and detergent treatment, acetone, and ultraviolet irradiation) that are thought to inactivate HTLV-III. These steps and the heat inactivation of serum specimens are likely to be important in rendering methods for anti-HTLV-III testing safe. The radioimmunoassay and immunofluorescence tests will also be convenient alternatives to the cumbersome "Western" blot procedure for verifying positive results arising in the forthcoming commercial enzyme assays for anti-HTLV-III.
Our results show that since 1980 HTLV-III infection has become well established among British homosexuals attending sexually transmitted disease clinics. Most of the patients sampled were originally investigated for hepatitis B infection and, as the risk of this correlates with promiscuity,i" this implies that they were more sexually active than other homosexuals. Among clinic patients, however, they were probably not a highly selected group. The prevalences of anti-HTLV-III in patients from the two centres A and E, where all homosexual patients attending clinics were sampled over about three months in 1984, were respectively the lowest and the highest in provincial centres. This suggests that confining testing in the other centres to samples taken to diagnose hepatitis B virus did not lead to a distorted picture of the prevalence of anti-HTLV-III in homosexuals attending sexually transmitted disease clinics.
Our data on British haemophiliacs show that, though infection may have appeared somewhat later, their prevalence of anti-HTLV-III is now higher than that of sexually active homosexuals. Moreover, the general antibody prevalence found in British haemophiliacs conceals a prevalence above 50°, in patients who have regularly received imported factor VIII concentrates (Moffat EH, et al, submitted for publication). Most seroconversions occurred in 1983 and 1984, and it is reasonable to suppose that the American factor VIII concentrate was mainly responsible. More American than domestic concentrate is used in Britain, and the higher incidence of AIDS and AIDS related disease in the United States implies that HTLV-III infection is more prevalent in the American than the British blood donor population. Concentrates are made from pools of many thousand donations and a single HTLV-III infected unit can probably contaminate an entire batch. Eventually the risk of infection will be diminished by screening all blood donations for anti-HTLV-III and heating concentrates to destroy the virus. In the meantime seronegative haemophiliacs must be identified and treated with heated concentrates.
The survey of British drug abusers, carried out on 1984 sera, shows that the prevalence of anti-HTLV-III already noted in this group remains low,6 even in a selected group whose main underlying disease, hepatitis B, implies intravenous administration of drugs and therefore an increased likelihood of blood borne infection. Nevertheless, a recent study of drug abusers in New York showed 870) to be infected,5 and HTLV-III infection might readily spread among intravenous drug abusers here, just as other viruses such as hepatitis B virus and hepatitis D virus (8 agent) have done.'2 In Central Africa, where AIDS is common and increasing in incidence, heterosexual intercourse seems to be the main mode of spread of HTLV-III.'3 In Britain, drug abusers and haemophiliacs are two groups from which it is possible that HTLV-III infection may spread by this route. This is the second seroepidemiological survey of HTLV-III infection in Britain. It confirms the results of the first6 and extends them in two respects: it showq that the infection has become increasingly widespread since 1980-1 in the two groups mainly affected and that HTLV-III has become prevalent in homosexuals throughout the country. The prevalence of anti-HTLV-III in the provinces is likely to increase as it has done in London, and further spread of infection can be avoided only by homosexuals very strictly limiting the numbers of sexual partners and preventing the transfer of semen. These are measures that must be urged on individuals, both through homosexual support groups and through adequate counselling services. Similarly, the potential for further spread of infection among haemophiliacs, other blood recipients, and drug abusers is a pressing problem demanding new resources to support prophylactic measures.
Because the epidemiological factors may change it is impossible to predict how many cases of AIDS there will be in Britain in the next few years. Though at first sight the outbreak is small and circumscribed, there is a constant upward trend and no signs of a plateau in the rate The needs of seropositive individuals, an unknown proportion of whom will develop AIDS related illness, must also be considered. The finding that some British patients were seropositive as long ago as 1980 should prompt investigation of their long term health. These studies, though difficult to mount, will be very important in planning for future care. At present there is insufficient provision for the advice and treatment of HTLV-III infected patients. The evidence from seroepidemiological surveys and continuing laboratory investigations of the HTLV-III epidemic point to a need for a rapid, adequate, and humane response to the predicament of those who have and will become infected.
SHORT REPORTS Fenclofenac induced interstitial nephritis confirmed by inadvertent rechallenge
Fenclofenac is a phenylacetic acid derived non-steroidal antiinflammatory drug which has been in wide use for about eight years. Side effects are similar to those of other non-steroidal anti-inflammatory agents and have included a diminution of renal function and occasional proteinuria. Allergic interstitial nephritis has been frequently reported after treatment with propionic acid derivatives such as fenoprofen.1 2 There have been only two reports of this complication after fenclofenac, however, and on each occasion additional drugs had been prescribed. We have recently seen a case of biopsy proved allergic interstitial nephritis associated with fenclofenac which recurred when the patient was inadvertently rechallenged with the drug.
Case report
A 65 year old man developed acute oliguric renal failure while on holiday in Israel. The oliguria was associated w.ith arthralgia and an erythematous rash. The patient admitted ingestion of Fnterosan (a proprietary antidiarrhoeal preparation) but denied use of any other drugs.
Investigation disclosed proteinuria in a small volume of urine, a plasma creatinine concentration of 1045 JLmol 1 (118 mg'l00 ml), and an absolute eosinophil count of 1-6 X 10',, 1. Intermittent haemodialvsis was begun
